ZA954374B - New lipid esters of nucleoside monophosphates use as immunosuppresive drugs - Google Patents

New lipid esters of nucleoside monophosphates use as immunosuppresive drugs

Info

Publication number: ZA954374B
Authority: ZA; South Africa
Prior art keywords: desoxy; chain; branched; saturated; straight
Prior art date: 1994-05-28

Application number

ZA954374A

Other languages

English (en)

Inventor

Dieter Herrmann

Hans-Georg Optiz

Harald Zilch

Alfred Mertens

Original Assignee

Boehringer Mannheim Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-28

Filing date

1995-05-29

Publication date

1996-11-29

1995-05-29 Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh

1996-11-29 Publication of ZA954374B publication Critical patent/ZA954374B/xx

Links

-1 lipid esters Chemical class 0.000 title abstract 3
239000003814 drug Substances 0.000 title abstract 2
229940079593 drug Drugs 0.000 title abstract 2
239000002777 nucleoside Substances 0.000 title abstract 2
230000001506 immunosuppresive effect Effects 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
229920006395 saturated elastomer Polymers 0.000 abstract 2
AYWFLOPQIYDGTP-RJDJZVBFSA-N (2R,3S,4R,5R)-4-amino-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol 4-amino-1-[(2R,3R,4S,5R)-3-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one (2R,3S,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol (2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-azido-2-(hydroxymethyl)oxolan-3-ol 5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound FC=1N=C(C=2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2N1)N.FC=1C(NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C1)=O)=O.N(=[N+]=[N-])[C@H]1[C@@H](O[C@@H]([C@H]1O)CO)N1C(=O)N=C(N)C=C1.N(=[N+]=[N-])[C@H]1[C@@H](O[C@@H]([C@H]1O)CO)N1C=NC=2C(N)=NC=NC12.N[C@H]1[C@@H](O[C@@H]([C@H]1O)CO)N1C=NC=2C(N)=NC=NC12 AYWFLOPQIYDGTP-RJDJZVBFSA-N 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
150000007522 mineralic acids Chemical class 0.000 abstract 1
150000007524 organic acids Chemical class 0.000 abstract 1
235000005985 organic acids Nutrition 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Transplantation (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

ZA954374A 1994-05-28 1995-05-29 New lipid esters of nucleoside monophosphates use as immunosuppresive drugs ZA954374B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4418690A DE4418690A1 (de)	1994-05-28	1994-05-28	Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel

Publications (1)

Publication Number	Publication Date
ZA954374B true ZA954374B (en)	1996-11-29

Family

ID=6519215

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA954374A ZA954374B (en)	1994-05-28	1995-05-29	New lipid esters of nucleoside monophosphates use as immunosuppresive drugs

Country Status (27)

Country	Link
US (1)	US6025343A (de)
EP (2)	EP0763049B1 (de)
JP (1)	JP3802057B2 (de)
KR (1)	KR100279087B1 (de)
CN (1)	CN1168735C (de)
AT (2)	ATE236189T1 (de)
AU (1)	AU688516B2 (de)
BR (1)	BR9507785A (de)
CA (1)	CA2190983C (de)
CZ (1)	CZ291846B6 (de)
DE (3)	DE4418690A1 (de)
DK (2)	DK1229040T3 (de)
ES (2)	ES2199250T3 (de)
FI (1)	FI117673B (de)
HU (1)	HU220336B (de)
IL (1)	IL113865A (de)
MX (1)	MX9605809A (de)
NO (1)	NO308998B1 (de)
NZ (1)	NZ287434A (de)
PL (1)	PL185290B1 (de)
PT (2)	PT1229040E (de)
RU (1)	RU2165429C2 (de)
SK (1)	SK284207B6 (de)
TW (1)	TW420686B (de)
UA (1)	UA45339C2 (de)
WO (1)	WO1995032984A1 (de)
ZA (1)	ZA954374B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458772B1 (en)	1909-10-07	2002-10-01	Medivir Ab	Prodrugs
JP3839857B2 (ja) *	1994-09-20	2006-11-01	塩野義製薬株式会社	エーテル型チオリン脂質化合物の製造方法
NZ297100A (en) *	1994-12-13	1997-10-24	Akira Matsuda	3'-substituted nucleoside derivatives; medicaments
WO1999051613A1 (en) *	1998-04-03	1999-10-14	Medivir Ab	Prodrugs of phosphorous-containing pharmaceuticals
BR9915555A (pt)	1998-11-05	2002-01-15	Centre Nat Rech Scient	Composto, composição e uso de ß - l- (2' ou 3' -azido) - 2', 3' -didesóxi -5-flúor citosina para o tratamento de infecção por vìrus de hepatite b
US6407077B1 (en)	1998-11-05	2002-06-18	Emory University	β-L nucleosides for the treatment of HIV infection
DE19855963A1 (de) *	1998-12-04	2000-06-08	Herbert Schott	Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
US7026469B2 (en)	2000-10-19	2006-04-11	Wake Forest University School Of Medicine	Compositions and methods of double-targeting virus infections and cancer cells
CA2390441A1 (en) *	1999-11-08	2001-05-17	Origenix Technologies, Inc.	Combinatorial library synthesis and pharmaceutically active compounds produced thereby
US6787526B1 (en)	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en)	2000-06-15	2005-04-05	Idenix Pharmaceuticals, Inc.	3′-prodrugs of 2′-deoxy-β-L-nucleosides
US6734294B2 (en) *	2001-01-22	2004-05-11	Chad C. Nelson	Isotopically enriched nucleic acids and associated methods for the production and purification thereof
US6881831B2 (en)	2001-05-16	2005-04-19	Migenix Inc.	Nucleic acid-based compounds and methods of use thereof
NZ533094A (en) *	2001-11-21	2006-01-27	Heidelberg Pharma Gmbh	Phospholipid derivatives of nucleosides as antitumoral medicaments
EP1831225A2 (de)	2004-11-19	2007-09-12	The Regents of the University of California	Entzündungshemmende pyrazolopyrimidine
RU2322450C2 (ru) *	2004-11-25	2008-04-20	Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ"	Модифицированные 5'-фосфонаты азт в качестве активных компонентов для потенциальных противовирусных препаратов
ES2401285T3 (es)	2004-12-16	2013-04-18	The Regents Of The University Of California	Fármacos con el pulmón como diana
CN101132795B (zh)	2004-12-30	2011-09-21	梅迪弗股份公司	用于hiv治疗的化合物
GB0505781D0 (en)	2005-03-21	2005-04-27	Univ Cardiff	Chemical compounds
ITRM20050391A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione.
AU2006271164A1 (en) *	2005-07-22	2007-01-25	Giuliani International Limited	Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation
EA200870409A1 (ru)	2006-04-04	2009-04-28	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Антагонисты киназы pi3
GB0608876D0 (en)	2006-05-05	2006-06-14	Medivir Ab	Combination therapy
US7378401B2 (en)	2006-07-14	2008-05-27	Heidelberg Pharma Gmbh	Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
MX2010000424A (es)	2007-07-09	2010-08-10	Easter Virginia Medical School	Derivados de nucleosidos sustituidos con propiedades antivirales y antimicrobianas.
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
CA2711558C (en)	2008-01-04	2016-12-13	Intellikine, Inc.	Phosphatidyl inositol-3 kinase inhibiting compounds
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
WO2010006072A2 (en)	2008-07-08	2010-01-14	The Regents Of The University Of California	Mtor modulators and uses thereof
AU2009268611B2 (en)	2008-07-08	2015-04-09	Intellikine, Llc	Kinase inhibitors and methods of use
JP5731978B2 (ja)	2008-09-26	2015-06-10	インテリカイン，エルエルシー	複素環キナーゼ阻害剤
CA2740885C (en)	2008-10-16	2018-04-03	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (de)	2009-05-07	2019-05-01	Intellikine, LLC	Heterocyclische verbindungen und ihre verwendung
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
AU2011255218B2 (en)	2010-05-21	2015-03-12	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja)	2010-11-10	2013-12-26	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環化合物及びその使用
AU2012205669B2 (en)	2011-01-10	2015-08-20	Infinity Pharmaceuticals Inc.	Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP6130305B2 (ja)	2011-02-23	2017-05-17	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
JP6027610B2 (ja)	2011-07-19	2016-11-16	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環式化合物及びその使用
US9056877B2 (en)	2011-07-19	2015-06-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP2751093A1 (de)	2011-08-29	2014-07-09	Infinity Pharmaceuticals, Inc.	Heterocyclische verbindungen und ihre verwendung
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
MX2015003874A (es)	2012-09-26	2015-12-16	Univ California	Modulacion de ire1.
KR102229478B1 (ko)	2012-11-01	2021-03-18	인피니티 파마슈티칼스, 인코포레이티드	Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
SMT201800538T1 (it)	2013-03-15	2019-01-11	Univ California	Diesteri di fosfonato nucleosidico aciclico
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
PE20160685A1 (es)	2013-10-04	2016-07-23	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
SG10201808053XA (en)	2014-03-19	2018-10-30	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
DE102014112055A1 (de) *	2014-08-22	2016-02-25	Universität Hamburg	Di- und Triphosphat-Propharmaka
HRP20220651T1 (hr)	2014-09-15	2022-08-19	The Regents Of The University Of California	Nukleotidni analozi
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en)	2015-09-14	2018-12-25	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10377782B2 (en)	2015-09-15	2019-08-13	The Regents Of The University Of California	Nucleotide analogs
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX391135B (es)	2016-06-24	2025-03-21	Infinity Pharmaceuticals Inc	Terapias de combinacion.
JP2025526212A (ja)	2022-07-21	2025-08-13	アンティババイオサイエンシズインコーポレイテッド	Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形
AU2024352221A1 (en) *	2023-09-26	2026-04-09	Board Of Regents Of The University Of Nebraska	Phosphonate prodrugs and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2930904A1 (de) *	1979-07-30	1981-02-19	Kailash Kumar Dr Gauri	Verwendung von 5-alkyl-pyrimidinnucleosiden bei der bekaempfung von krebs
US4783402A (en) *	1983-04-11	1988-11-08	Meito Sangyo Kabushiki Kaisha	Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique
FR2580283B1 (fr) *	1985-04-15	1989-11-24	Toyo Jozo Kk	Nouveau conjugue nucleoside-phospholipide
EP0262876B1 (de) *	1986-09-27	1992-04-29	Toyo Jozo Kabushiki Kaisha	Nukleosid-Phospholipid-Konjugat
JP2796089B2 (ja) *	1986-10-06	1998-09-10	旭化成工業株式会社	リン脂質誘導体の製造法
DE3730542A1 (de) *	1987-09-11	1989-04-06	Hoechst Ag	Arzneimittel mit einem gehalt an bestimmten 6-mercaptopurin-derivaten, verwendung dieser 6-mercaptopurin-derivate, verfahren zur herstellung der arzneimittel sowie einige neue 6-mercaptopurin-derivate und verfahren zu deren herstellung
US5463092A (en) *	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
DE4026265A1 (de) *	1990-08-20	1992-02-27	Boehringer Mannheim Gmbh	Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5563257A (en) *	1990-08-20	1996-10-08	Boehringer Mannheim Gmbh	Phospholipid derivatives of nucleosides
DE4111730A1 (de) *	1991-04-10	1992-10-15	Knoll Ag	Neue cytarabin-derivate, ihre herstellung und verwendung
AU668873B2 (en) *	1991-07-12	1996-05-23	Chimerix, Inc.	Antiviral liponucleosides: treatment of hepatitis B
DE4204032A1 (de) *	1992-02-12	1993-08-19	Boehringer Mannheim Gmbh	Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
US5512671A (en) *	1993-02-16	1996-04-30	Wake Forest University	Ether lipid-nucleoside covalent conjugates

1994
- 1994-05-28 DE DE4418690A patent/DE4418690A1/de not_active Withdrawn
1995
- 1995-05-23 DK DK02008360T patent/DK1229040T3/da active
- 1995-05-23 JP JP50026296A patent/JP3802057B2/ja not_active Expired - Fee Related
- 1995-05-23 AT AT95920864T patent/ATE236189T1/de not_active IP Right Cessation
- 1995-05-23 CN CNB951943715A patent/CN1168735C/zh not_active Expired - Fee Related
- 1995-05-23 NZ NZ287434A patent/NZ287434A/en not_active IP Right Cessation
- 1995-05-23 WO PCT/EP1995/001951 patent/WO1995032984A1/en not_active Ceased
- 1995-05-23 PT PT02008360T patent/PT1229040E/pt unknown
- 1995-05-23 DK DK95920864T patent/DK0763049T3/da active
- 1995-05-23 ES ES95920864T patent/ES2199250T3/es not_active Expired - Lifetime
- 1995-05-23 PT PT95920864T patent/PT763049E/pt unknown
- 1995-05-23 KR KR1019960706690A patent/KR100279087B1/ko not_active Expired - Fee Related
- 1995-05-23 DE DE69530197T patent/DE69530197T2/de not_active Expired - Fee Related
- 1995-05-23 EP EP95920864A patent/EP0763049B1/de not_active Expired - Lifetime
- 1995-05-23 BR BR9507785A patent/BR9507785A/pt not_active Application Discontinuation
- 1995-05-23 SK SK1518-96A patent/SK284207B6/sk not_active IP Right Cessation
- 1995-05-23 EP EP02008360A patent/EP1229040B8/de not_active Expired - Lifetime
- 1995-05-23 AU AU26154/95A patent/AU688516B2/en not_active Ceased
- 1995-05-23 AT AT02008360T patent/ATE249472T1/de not_active IP Right Cessation
- 1995-05-23 HU HU9603269A patent/HU220336B/hu not_active IP Right Cessation
- 1995-05-23 MX MX9605809A patent/MX9605809A/es not_active IP Right Cessation
- 1995-05-23 UA UA96114469A patent/UA45339C2/uk unknown
- 1995-05-23 ES ES02008360T patent/ES2206429T3/es not_active Expired - Lifetime
- 1995-05-23 CZ CZ19963477A patent/CZ291846B6/cs not_active IP Right Cessation
- 1995-05-23 RU RU96124383/04A patent/RU2165429C2/ru active
- 1995-05-23 CA CA002190983A patent/CA2190983C/en not_active Expired - Fee Related
- 1995-05-23 DE DE69531749T patent/DE69531749T2/de not_active Expired - Fee Related
- 1995-05-24 TW TW084105233A patent/TW420686B/zh active
- 1995-05-25 IL IL113865A patent/IL113865A/en not_active IP Right Cessation
- 1995-05-29 ZA ZA954374A patent/ZA954374B/xx unknown
1996
- 1996-11-21 PL PL95317380A patent/PL185290B1/pl not_active IP Right Cessation
- 1996-11-27 FI FI964727A patent/FI117673B/fi active IP Right Grant
- 1996-11-27 NO NO965054A patent/NO308998B1/no not_active IP Right Cessation
- 1996-11-27 US US08/753,633 patent/US6025343A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2206429T3 (es)	2004-05-16
FI117673B (fi)	2007-01-15
FI964727A0 (fi)	1996-11-27
DE69530197T2 (de)	2004-01-29
FI964727L (fi)	1996-11-27
KR100279087B1 (ko)	2001-01-15
EP1229040B1 (de)	2003-09-10
CZ291846B6 (cs)	2003-06-18
NO308998B1 (no)	2000-11-27
SK284207B6 (en)	2004-11-03
EP1229040A2 (de)	2002-08-07
US6025343A (en)	2000-02-15
EP0763049B1 (de)	2003-04-02
JP3802057B2 (ja)	2006-07-26
CZ347796A3 (en)	1997-04-16
NO965054D0 (no)	1996-11-27
WO1995032984A8 (en)	2003-01-16
NZ287434A (en)	1998-01-26
IL113865A0 (en)	1995-08-31
DE69530197D1 (de)	2003-05-08
DE69531749D1 (de)	2003-10-16
CN1154111A (zh)	1997-07-09
MX9605809A (es)	1997-12-31
AU688516B2 (en)	1998-03-12
UA45339C2 (uk)	2002-04-15
ATE249472T1 (de)	2003-09-15
DE4418690A1 (de)	1996-01-11
EP1229040B8 (de)	2003-11-05
HU9603269D0 (en)	1997-01-28
PL185290B1 (pl)	2003-04-30
BR9507785A (pt)	1997-09-23
HUT75340A (en)	1997-05-28
IL113865A (en)	2008-12-29
SK151896A3 (en)	1997-06-04
DK1229040T3 (da)	2003-12-22
TW420686B (en)	2001-02-01
WO1995032984A1 (en)	1995-12-07
HU220336B (hu)	2001-12-28
KR970703354A (ko)	1997-07-03
DE69531749T2 (de)	2004-07-29
DK0763049T3 (da)	2003-07-28
RU2165429C2 (ru)	2001-04-20
CA2190983A1 (en)	1995-12-07
PT1229040E (pt)	2003-12-31
NO965054L (no)	1997-01-28
CN1168735C (zh)	2004-09-29
ES2199250T3 (es)	2004-02-16
JPH10500964A (ja)	1998-01-27
ATE236189T1 (de)	2003-04-15
EP0763049A1 (de)	1997-03-19
AU2615495A (en)	1995-12-21
PL317380A1 (en)	1997-04-01
CA2190983C (en)	2006-08-15
PT763049E (pt)	2003-08-29
EP1229040A3 (de)	2002-08-21

Publication	Publication Date	Title
HUT75340A (en)	1997-05-28	New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs
HUT50841A (en)	1990-03-28	Process for producing (cycloalkylamino)-methylene-bis(phosphoric acid) derivatives and pharmaceutical compositions comprising such compounds as active ingredient
KR960000230A (ko)	1996-01-25	간담즙성 질병 치료제
ES514240A0 (es)	1984-04-16	Un procedimiento para la prepracion de nuevos derivados de acidos 2-carbamimidoil-1-,carbadestiapen-2-en-3-carboxilados.
TW343975B (en)	1998-11-01	New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
SE8700914L (sv)	1987-03-04	Anvendning av adenosinderivat
PT82547A (en)	1986-06-01	Hexenoic acids
ATE198746T1 (de)	2001-02-15	Pyrimidinderivate und pharmazeutische zusammensetzungen
HUT48259A (en)	1989-05-29	Herbicide compositions containing new macrolide active components, and process for producing new macrolide compounds and pharmaceutical compositions containing them as active components
ATE309212T1 (de)	2005-11-15	Optisch aktive 1-phenylpyrrolidonderivate
IT1248558B (it)	1995-01-19	Derivati della fisovenina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.